Key Financial Data Of Group

Oncolys BioPharma Inc. - Filing #7595769

Concept As at
2022-06-30
2022-04-01 to
2022-06-30
2022-01-01 to
2022-06-30
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-06-30
As at
2021-06-30
2021-04-01 to
2021-06-30
Key financial data of group
Business results of group
Net sales
426,152,000 JPY
642,494,000 JPY
193,067,000 JPY
Ordinary profit (loss)
-590,514,000 JPY
-1,500,888,000 JPY
-649,015,000 JPY
Net assets
2,737,637,000 JPY
3,593,992,000 JPY
4,480,847,000 JPY
Total assets
3,504,831,000 JPY
4,291,876,000 JPY
5,197,403,000 JPY
Basic earnings (loss) per share
-13.94
-32.92
-95.50
-39.45
-17.35
Diluted earnings per share
Equity-to-asset ratio
0.779 xbrli:pure
0.836 xbrli:pure
0.861 xbrli:pure
Net cash provided by (used in) operating activities
-722,482,000 JPY
-1,741,827,000 JPY
-594,589,000 JPY
Net cash provided by (used in) investing activities
20,841,000 JPY
-942,000 JPY
-327,000 JPY
Net cash provided by (used in) financing activities
29,599,000 JPY
3,091,384,000 JPY
3,148,769,000 JPY
Cash and cash equivalents
2,613,656,000 JPY
3,209,635,000 JPY
4,402,007,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.